Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
EQS Group
Issuer: Mainz BioMed N.V. / Key word(s): Study results
25.04.2024 / 15:29 CET/CEST
The issuer is solely responsible for..